145 related articles for article (PubMed ID: 33297847)
1. Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center.
Moore DC; Gebru T; Plesca D
J Oncol Pharm Pract; 2021 Dec; 27(8):1914-1918. PubMed ID: 33297847
[TBL] [Abstract][Full Text] [Related]
2. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits.
Swan JT; Zaghloul HA; Cox JE; Murillo JR
Pharmacotherapy; 2014 Jul; 34(7):686-94. PubMed ID: 24706572
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Pharmacist-Developed, Nurse-Driven Protocol for Management of Parenteral Anticancer Therapy Infusion Reactions in an Ambulatory Infusion Center.
Cebollero J; LaFollette JA; Walton SM; Adams Curry M
J Oncol Pharm Pract; 2023 Jun; 29(4):802-809. PubMed ID: 35164607
[TBL] [Abstract][Full Text] [Related]
4. Implementation and Evaluation of a 90-Minute Rituximab Infusion Protocol at the Richard L. Roudebush VA Medical Center.
Fenton TT; Crawford BS; Bullington SM
Fed Pract; 2020 Jul; 37(7):331-335. PubMed ID: 32908338
[TBL] [Abstract][Full Text] [Related]
5. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
6. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
[TBL] [Abstract][Full Text] [Related]
8. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
Courville J; Nastoupil L; Kaila N; Kelton J; Zhang J; Alcasid A; Nava-Parada P
BioDrugs; 2021 Jul; 35(4):459-468. PubMed ID: 34152584
[TBL] [Abstract][Full Text] [Related]
9. Rapid rituximab infusion, local center experience.
Monem EA; Al-Bahrani B; Mehdi I; Nada A
Gulf J Oncolog; 2013 Jul; 1(14):52-6. PubMed ID: 23996867
[TBL] [Abstract][Full Text] [Related]
10. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.
Tsutsumi D; Hayama T; Miura K; Uchiike A; Tsuboi S; Otsuka S; Hatta Y; Kishikawa Y
Int J Clin Pharm; 2022 Apr; 44(2):366-373. PubMed ID: 34894347
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.
Hong J; Kim JY; Ahn HK; Lee SM; Sym SJ; Park J; Cho EK; Ahn JY; Park S; Lee SP; Shin DB; Lee JH
Support Care Cancer; 2013 Apr; 21(4):1145-52. PubMed ID: 23111943
[TBL] [Abstract][Full Text] [Related]
12. Infusion-related reactions to rituximab: frequency, mechanisms and predictors.
Paul F; Cartron G
Expert Rev Clin Immunol; 2019 Apr; 15(4):383-389. PubMed ID: 30580638
[TBL] [Abstract][Full Text] [Related]
13. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
14. A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center.
Chiang J; Chan A; Shih V; Hee SW; Tao M; Lim ST
Int J Hematol; 2010 Jun; 91(5):826-30. PubMed ID: 20461562
[TBL] [Abstract][Full Text] [Related]
15. Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Lang D; George C
JBI Libr Syst Rev; 2011; 9(1):1-30. PubMed ID: 27819968
[TBL] [Abstract][Full Text] [Related]
16. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
17. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.
Schwartzberg LS; Stepanski EJ; Fortner BV; Houts AC
Support Care Cancer; 2008 Apr; 16(4):393-8. PubMed ID: 17909865
[TBL] [Abstract][Full Text] [Related]
18. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.
Hayama T; Miura K; Uchiike A; Nakagawa M; Tsutsumi D; Sakagami M; Yoshida Y; Takei M
Int J Clin Pharm; 2017 Apr; 39(2):380-385. PubMed ID: 28144804
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
[TBL] [Abstract][Full Text] [Related]
20. Rapid infusion of rituximab over 60 min.
Tuthill M; Crook T; Corbet T; King J; Webb A
Eur J Haematol; 2009 Apr; 82(4):322-5. PubMed ID: 19220420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]